Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).

NCT01776424 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01776424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01776424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2013
Completion date
June 15, 2021
Enrollment
27,395 (actual)
Sites
565

Conditions

As the registry lists them; a condition with its own page is linked.

prevention & control